In recent years, multiple myeloma has quietly entered the lives of many middle-aged and elderly people, and the topic about it is no longer unfamiliar. Myeloma occurs in middle-aged and elderly people and is characterized by bone pain, anemia, recurrent infections, kidney damage, and extramedullary masses, and has now become the second most common malignancy of the hematological system. As the understanding of multiple myeloma has improved, there have been many advances in treatment. However, myeloma remains an incurable disease, and almost all patients sooner or later still relapse, progress, and become drug-resistant. In any case, the survival time of patients has been significantly extended from the previous average of 3.5 years, with some reaching more than 10 years, and they can have a good quality of life. Current treatments for myeloma include chemotherapy, targeted therapy, radiotherapy, immunotherapy, transplantation, and clinical trials. As clinicians, we often hear voices during the treatment process, such as: Why is your regimen different from others? Or why is the same regimen not as effective as others? The simple answer is that each patient’s specific situation is different, mainly including age, comorbidities, physical condition, malignancy of tumor cells and drug sensitivity, and of course, some economic and psychological factors. There are also some patients or family members who do not know enough about the treatment or only focus on the various possible adverse effects of chemotherapy, and eventually miss the timing of treatment and deterioration of the disease. When choosing a regimen, we will fully consider the patient’s disease status, physical condition, possible adverse drug reactions, and economic situation, etc., and develop a corresponding individualized regimen to avoid the decrease in the patient’s quality of life or even death, increase in unnecessary medical expenses, etc., brought about by the treatment. In conclusion, the treatment of multiple myeloma does not happen overnight. From induction therapy, to consolidation and intensification, to maintenance, to retreatment after relapse, patients and their families should be prepared for a “protracted battle”, communicate with clinicians in a timely manner, accept standardized treatment, and actively participate in clinical trials. In the face of tumor, do not stop because of fear and ignorance, but go forward with hope and optimism.